- 1、本文档共15页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
daclatasvir plus sofosbuvir for hcv infection an oral
Accepted Manuscript
International hepatology
Daclatasvir plus Sofosbuvir for HCV infection: An oral combination therapy
with high antiviral efficacy
Tarik Asselah
PII: S0168-8278(14)00305-5
DOI: /10.1016/j.jhep.2014.04.042
Reference: JHEPAT 5147
To appear in: Journal of Hepatology
Received Date: 2 March 2014
Revised Date: 20 April 2014
Accepted Date: 23 April 2014
Please cite this article as: Asselah, T., Daclatasvir plus Sofosbuvir for HCV infection: An oral combination therapy
with high antiviral efficacy, Journal of Hepatology (2014), doi: /10.1016/j.jhep.2014.04.042
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1
Daclatasvir plus Sofosbuvir for HCV infection: An oral combination
therapy with high antiviral efficacy
Tarik Asselah
Centre de Recherche sur l’Inflammation (CRI), UMR 1 149 Inserm, Université Paris
Diderot, Service d’Hépatologie, AP-HP Hôpital Beaujon, Clichy-France.
Keywords: Daclatasvir; Direct-acting antivirals; Simeprevir; Faldaprevir; Sofosbuvir.
*Corresponding author. Address: Centre de Recherche sur l’Inflammation (CRI),
UMR 1149 Inserm, Université Paris Diderot, Service d’Hépatologie, AP-HP Hôpital
Beaujon, Clichy-France, 100 Bd du Général Leclerc, Clichy 92110, France. Tel.:
+33(0) 140875579; fax: +33(
您可能关注的文档
- comment on neil h. buchananâ s social security and government.pdf
- coming together after the crisis global convergence of.pdf
- comments on “calibrated surface temperature forecasts from the.pdf
- communicating asset risk how name recognition and the format.pdf
- common structures of asset-backed securities and their risks.pdf
- color compatibility from large datasets - university of.pdf
- communicating quantum strongprocessesstrong - university of glasgow.pdf
- commercial law - single shareholder company.pdf
- communications in information and strongsystemsstrong c vol. 9, no. 1, pp..pdf
- communication networking schemes for wide area electric.pdf
最近下载
- 2024年广东省初中学业水平考试模拟地理试卷(一)课件.pptx VIP
- 广州洪德巷历史文化街区保护利用规划.pdf
- 广州市人民南历史文化街区保护利用规划(文本+图纸).pdf VIP
- 关于烹饪的策划书3.pptx
- WALL·E《机器人总动员(2008)》完整中英文对照剧本.pdf VIP
- LDT 99.13-2008 建设工程劳动定额市政工程-维修养护工程.docx
- 实验报告之spss频数分析.docx VIP
- 新教科版科学小学科学五年级下册全册教案(表格式,可打印).docx
- 2022年新改版教科版五年级上册科学全册教案教学设计(新整理版).doc
- 某小区高楼变频恒压供水系统设计.docx
文档评论(0)